The 36-month beta value for DRIO is also noteworthy at 1.56. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DRIO is 24.83M, and at present, short sellers hold a 5.42% of that float. The average trading volume of DRIO on May 24, 2024 was 137.31K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DRIO) stock’s latest price update
DarioHealth Corp (NASDAQ: DRIO)’s stock price has dropped by -8.05 in relation to previous closing price of 1.74. Nevertheless, the company has seen a loss of -14.89% in its stock price over the last five trading days. zacks.com reported 2024-05-15 that DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.45 per share a year ago.
DRIO’s Market Performance
DRIO’s stock has fallen by -14.89% in the past week, with a monthly rise of 6.67% and a quarterly drop of -21.18%. The volatility ratio for the week is 9.55% while the volatility levels for the last 30 days are 8.89% for DarioHealth Corp The simple moving average for the past 20 days is -2.71% for DRIO’s stock, with a -20.16% simple moving average for the past 200 days.
Analysts’ Opinion of DRIO
Many brokerage firms have already submitted their reports for DRIO stocks, with Alliance Global Partners repeating the rating for DRIO by listing it as a “Buy.” The predicted price for DRIO in the upcoming period, according to Alliance Global Partners is $8.75 based on the research report published on May 13, 2022 of the previous year 2022.
Cowen, on the other hand, stated in their research note that they expect to see DRIO reach a price target of $31. The rating they have provided for DRIO stocks is “Outperform” according to the report published on April 22nd, 2021.
Stifel gave a rating of “Buy” to DRIO, setting the target price at $30 in the report published on March 23rd of the previous year.
DRIO Trading at 7.24% from the 50-Day Moving Average
After a stumble in the market that brought DRIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.07% of loss for the given period.
Volatility was left at 8.89%, however, over the last 30 days, the volatility rate increased by 9.55%, as shares surge +8.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.23% lower at present.
During the last 5 trading sessions, DRIO fell by -14.89%, which changed the moving average for the period of 200-days by -53.76% in comparison to the 20-day moving average, which settled at $1.6510. In addition, DarioHealth Corp saw -6.98% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRIO
Current profitability levels for the company are sitting at:
- -3.2 for the present operating margin
- 0.28 for the gross margin
The net margin for DarioHealth Corp stands at -0.98. The total capital return value is set at -0.51. Equity return is now at value -65.91, with -40.37 for asset returns.
Based on DarioHealth Corp (DRIO), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -1.32. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is -102.21.
Currently, EBITDA for the company is -50.84 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 2.26. The receivables turnover for the company is 2.42for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
In summary, DarioHealth Corp (DRIO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
